Limits...
A summary of the new GINA strategy: a roadmap to asthma control.

Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, Haahtela T, Hurd SS, Inoue H, de Jongste JC, Lemanske RF, Levy ML, O'Byrne PM, Paggiaro P, Pedersen SE, Pizzichini E, Soto-Quiroz M, Szefler SJ, Wong GW, FitzGerald JM - Eur. Respir. J. (2015)

Bottom Line: However, uptake of existing guidelines is poor.A major revision of the GINA report was published in 2014, and updated in 2015, reflecting an evolving understanding of heterogeneous airways disease, a broader evidence base, increasing interest in targeted treatment, and evidence about effective implementation approaches.During development of the report, the clinical utility of recommendations and strategies for their practical implementation were considered in parallel with the scientific evidence.This article provides a summary of key changes in the GINA report, and their rationale.

View Article: PubMed Central - PubMed

Affiliation: Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia helen.reddel@sydney.edu.au.

No MeSH data available.


Related in: MedlinePlus

The Global Initiative for Asthma (GINA) control-based cycle of asthma care. This figure highlights key priorities in management of asthma in the GINA global asthma strategy. Further details can be found in boxes 3–3 and 3–5 in the full GINA 2015 report (“Global Strategy for Asthma Management and Prevention”), available online (www.ginasthma.org). ICS: inhaled corticosteroids. Figure modified with permission of GINA.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4554554&req=5

Figure 1: The Global Initiative for Asthma (GINA) control-based cycle of asthma care. This figure highlights key priorities in management of asthma in the GINA global asthma strategy. Further details can be found in boxes 3–3 and 3–5 in the full GINA 2015 report (“Global Strategy for Asthma Management and Prevention”), available online (www.ginasthma.org). ICS: inhaled corticosteroids. Figure modified with permission of GINA.

Mentions:  • A control-based asthma management cycle (assess – adjust treatment – review response), to prompt a comprehensive but clinically feasible approach (figure 1)


A summary of the new GINA strategy: a roadmap to asthma control.

Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, Haahtela T, Hurd SS, Inoue H, de Jongste JC, Lemanske RF, Levy ML, O'Byrne PM, Paggiaro P, Pedersen SE, Pizzichini E, Soto-Quiroz M, Szefler SJ, Wong GW, FitzGerald JM - Eur. Respir. J. (2015)

The Global Initiative for Asthma (GINA) control-based cycle of asthma care. This figure highlights key priorities in management of asthma in the GINA global asthma strategy. Further details can be found in boxes 3–3 and 3–5 in the full GINA 2015 report (“Global Strategy for Asthma Management and Prevention”), available online (www.ginasthma.org). ICS: inhaled corticosteroids. Figure modified with permission of GINA.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4554554&req=5

Figure 1: The Global Initiative for Asthma (GINA) control-based cycle of asthma care. This figure highlights key priorities in management of asthma in the GINA global asthma strategy. Further details can be found in boxes 3–3 and 3–5 in the full GINA 2015 report (“Global Strategy for Asthma Management and Prevention”), available online (www.ginasthma.org). ICS: inhaled corticosteroids. Figure modified with permission of GINA.
Mentions:  • A control-based asthma management cycle (assess – adjust treatment – review response), to prompt a comprehensive but clinically feasible approach (figure 1)

Bottom Line: However, uptake of existing guidelines is poor.A major revision of the GINA report was published in 2014, and updated in 2015, reflecting an evolving understanding of heterogeneous airways disease, a broader evidence base, increasing interest in targeted treatment, and evidence about effective implementation approaches.During development of the report, the clinical utility of recommendations and strategies for their practical implementation were considered in parallel with the scientific evidence.This article provides a summary of key changes in the GINA report, and their rationale.

View Article: PubMed Central - PubMed

Affiliation: Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia helen.reddel@sydney.edu.au.

No MeSH data available.


Related in: MedlinePlus